At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
AL001drug
Likely dose
AL001 60 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9orf72 Mutations Causative of Frontotemporal Dementia
In Brief
A Phase 2 clinical trial evaluating AL001 for Frontotemporal Dementia. Completed, enrolled 33 participants across 12 sites in 6 countries.
Detailed Summary
A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrontotemporal Dementia
CountriesCanada, Germany, Italy, Netherlands, United Kingdom, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartSep 2019
Primary CompletionJun 2024
TodayJul 2026
First PostedJun 17, 2019
Enrollment StartSep 27, 2019
Primary CompletionJun 5, 2024
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 7.0 years ago
Interventions
AL001drug
60 mg/kg of AL001 every 4 weeks